Patents by Inventor E. Antonio Chiocca
E. Antonio Chiocca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230053817Abstract: The present application relates to sequences that enhance permeation of immunotherapy agents across the blood brain barrier (BBB), compositions comprising the sequences, and methods of use thereof to treat brain cancer, e.g., glioblastoma (GBM). Further disclosed are a number of potential targeting peptide sequences identified that enhance permeation through the BBB, when inserted into the capsid of an adeno-associated virus (AAV).Type: ApplicationFiled: January 8, 2021Publication date: February 23, 2023Inventors: Fengfeng Bei, E. Antonio Chiocca
-
Publication number: 20210380978Abstract: Compositions comprising inhibitory nucleic acids targeting the long non-coding RNA INCA1, and methods of use thereof, e.g., in combination with immunotherapy, to treat cancer.Type: ApplicationFiled: October 15, 2019Publication date: December 9, 2021Inventors: Marco Mineo, E. Antonio Chiocca
-
Publication number: 20100273258Abstract: A culture cell for growing animal cells in vitro has sides and a bottom forming a volume. The volume contains a layer of nanofiber upon which animal cells can be cultured. The layer of nanofiber can be oriented or non-oriented. Multiple layers can be placed in the volume, where the layers have different composition and/or different porosity. The nanofiber can be, for example, surface treated or of a core-shell construction.Type: ApplicationFiled: April 23, 2010Publication date: October 28, 2010Applicant: The Ohio State UniversityInventors: John J. Lannutti, Jed K. Johnson, E. Antonio Chiocca, Sara Nicole Fischer, Sean E. Lawler, Young C. Lin, Clay B. Marsh
-
Publication number: 20100143500Abstract: A method of treating a glial cell related disorder in a mammalian subject includes administering a drug which enhances or prolongs GSK-3 ? or ? inactivation.Type: ApplicationFiled: October 31, 2007Publication date: June 10, 2010Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Sean E. Lawler, Michal Oskar Nowicki, E. Antonio Chiocca
-
Patent number: 7514252Abstract: The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes ?34.5 gene.Type: GrantFiled: January 26, 2005Date of Patent: April 7, 2009Assignee: The General Hospital CorporationInventors: E. Antonio Chiocca, Richard Y. Chung
-
Patent number: 7214515Abstract: The present invention relates to HSV-based amplicon vectors carrying a genomic DNA fragment, and methods of constructing and using the same. Included within the present invention is a method of converting any large capacity DNA cloning vector, such as a BAC or PAC, into an HSV amplicon or hybrid HSV amplicon using site-specific, or other types of recombination, so that genomic DNA inserts within the BAC or PAC clone can be delivered by infection to a cell, and efficiently expressed. The present invention also relates to a system for the rapid creation of viral vectors carrying transgenes of interest. This aspect of the invention is accomplished through recombination between: (a) a large-capacity cloning vector carrying a viral genome, and (b) a transfer vector containing the transgene of interest. Finally, an expression-ready genomic DNA library is disclosed.Type: GrantFiled: January 4, 2002Date of Patent: May 8, 2007Assignee: The General Hospital CorporationInventors: E. Antonio Chiocca, Yoshinaga Saeki, Richard Wade-Martins
-
Patent number: 6897057Abstract: The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes ?34.5 gene.Type: GrantFiled: August 31, 2000Date of Patent: May 24, 2005Assignee: The General Hospital CorporationInventors: E. Antonio Chiocca, Richard Y. Chung
-
Patent number: 6849424Abstract: The invention relates to devices and methods for growing cells in vitro in an enclosed device that allows for a three-dimensional measurement over time of both their proliferative and/or invasive properties. By growing the cells in an enclosed matrix that resembles the environment that the cells confront in vivo, the cells can divide, invade, and form branched networks as they do in living tissue, e.g., in an individual. The devices of the invention include a test chamber in which cells, e.g., tumor cells, are placed and permitted to divide and/or invade. Cells can be placed within an insert within a chamber of the device. A delivery chamber that connects to the test chamber enables the delivery of agents that can be studied, e.g., for their therapeutic potential. The assay devices of the invention can be used as model systems to study cancer biology and to evaluate the efficacy of anti-cancer therapeutics.Type: GrantFiled: February 12, 2003Date of Patent: February 1, 2005Assignee: The General Hospital CorporationInventors: Thomas S. Deisboeck, E. Antonio Chiocca, John D. Wright
-
Publication number: 20040029209Abstract: The invention relates to devices and methods for growing cells in vitro in an enclosed device that allows for a three-dimensional measurement over time of both their proliferative and/or invasive properties. By growing the cells in an enclosed matrix that resembles the environment that the cells confront in vivo, the cells can divide, invade, and form branched networks as they do in living tissue, e.g., in an individual. The devices of the invention include a test chamber in which cells, e.g., tumor cells, are placed and permitted to divide and/or invade. Cells can be placed within an insert within a chamber of the device. A delivery chamber that connects to the test chamber enables the delivery of agents that can be studied, e.g., for their therapeutic potential. The assay devices of the invention can be used as model systems to study cancer biology and to evaluate the efficacy of anti-cancer therapeutics.Type: ApplicationFiled: February 12, 2003Publication date: February 12, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Thomas S. Deisboeck, E. Antonio Chiocca, John D. Wright
-
Patent number: 6602701Abstract: The invention relates to devices and methods for growing cells in vitro in an enclosed device that allows for a three-dimensional measurement over time of both their proliferative and/or invasive properties. By growing the cells in an enclosed matrix that resembles the environment that the cells confront in vivo, the cells can divide, invade, and form branched networks as they do in living tissue, e.g., in an individual. The devices of the invention include a test chamber in which cells, e.g., tumor cells, are placed and permitted to divide and/or invade. Cells can be placed within an insert within a chamber of the device. A delivery chamber that connects to the test chamber enables the delivery of agents that can be studied, e.g., for their therapeutic potential. The assay devices of the invention can be used as model systems to study cancer biology and to evaluate the efficacy of anti-cancer therapeutics.Type: GrantFiled: January 11, 2001Date of Patent: August 5, 2003Assignee: The General Hospital CorporationInventors: Thomas S. Deisboeck, E. Antonio Chiocca, John D. Wright
-
Patent number: 6602499Abstract: The present invention relates to viral mutants and methods of using these viral mutants for selectively killing neoplastic cells. The viral mutants of the invention are capable of selectively killing neoplastic cells by a combination of viral mediated oncolysis and anti-cancer (“suicide”) gene therapy.Type: GrantFiled: April 30, 1999Date of Patent: August 5, 2003Assignee: The General Hospital CorporationInventors: E. Antonio Chiocca, Xandra O. Breakefield
-
Patent number: 6573090Abstract: The present invention relates to an enhanced and simplified herpes virus amplicon packaging system. The packaging system comprises a herpes virus amplicon vector and a packaging vector. In one embodiment, the packaging vector comprises a bacterial artificial chromosome (BAC) containing the HSV-1 genome. The packaging vector contains an intact pac site but is otherwise rendered packaging defective. The packaging vector can be rendered packaging defective by inserting nucleotides into the pac site, or by otherwise interfering with the capsid's ability to close, for example, by increasing the size of the DNA fragment upon which the herpes virus genome is cloned. This system can be used to package a wide range of nucleotide sequences (e.g., a therapeutic or antigenic gene) into an empty herpes virus particle taking advantage of the large transgene capacity of herpes viruses. This system can also be used as a vaccine to induce protective immunity against HSV-1, or other complex pathogens.Type: GrantFiled: December 9, 1999Date of Patent: June 3, 2003Assignees: The General Hospital Corporation, University Medical Centre St. Radboud of the University of Nijmegen, University of Zurich, The Walter & Eliza Hall Institute of Medical ResearchInventors: Xandra O. Breakefield, E. Antonio Chiocca, Yoshinaga Saeki, Cornel Fraefel, Kurt Tobler, Mathias Ackermann, Mark Suter, Gosse J. Adema, Ken Shortman
-
Patent number: 6544781Abstract: The present invention relates to a viral vector system derived from Epstein-Barr Virus (EBV), where the transgene is effectively inserted into the EBV major internal repeat region (IR1) without adverse affect on EBV latent or lytic function. The vector of the invention can target and stably transform B-lymphocyte cells, both in culture and in vivo.Type: GrantFiled: July 17, 2000Date of Patent: April 8, 2003Assignee: The General Hospital CorporationInventors: Xiaoqun Jiang, E. Antonio Chiocca, Elliott Kieff, Fred Wang, Fred Hochberg
-
Publication number: 20020110543Abstract: The present invention relates to HSV-based amplicon vectors carrying a genomic DNA fragment, and methods of constructing and using the same. Included within the present invention is a method of converting any large capacity DNA cloning vector, such as a BAC or PAC, into an HSV amplicon or hybrid HSV amplicon using site-specific, or other types of recombination, so that genomic DNA inserts within the BAC or PAC clone can be delivered by infection to a cell, and efficiently expressed. The present invention also relates to a system for the rapid creation of viral vectors carrying transgenes of interest. This aspect of the invention is accomplished through recombination between: (a) a large-capacity cloning vector carrying a viral genome, and (b) a transfer vector containing the transgene of interest. Finally, an expression-ready genomic DNA library is disclosed.Type: ApplicationFiled: January 4, 2002Publication date: August 15, 2002Applicant: The General Hospital CorporationInventors: E. Antonio Chiocca, Yoshinaga Saeki, Richard Wade-Martins
-
Publication number: 20010031480Abstract: The invention relates to devices and methods for growing cells in vitro in an enclosed device that allows for a three-dimensional measurement over time of both their proliferative and/or invasive properties. By growing the cells in an enclosed matrix that resembles the environment that the cells confront in vivo, the cells can divide, invade, and form branched networks as they do in living tissue, e.g., in an individual. The devices of the invention include a test chamber in which cells, e.g., tumor cells, are placed and permitted to divide and/or invade. Cells can be placed within an insert within a chamber of the device. A delivery chamber that connects to the test chamber enables the delivery of agents that can be studied, e.g., for their therapeutic potential. The assay devices of the invention can be used as model systems to study cancer biology and to evaluate the efficacy of anti-cancer therapeutics.Type: ApplicationFiled: January 11, 2001Publication date: October 18, 2001Inventors: Thomas S. Deisboeck, John D. Wright, E. Antonio Chiocca
-
Patent number: 5688773Abstract: A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targets the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.Type: GrantFiled: October 28, 1994Date of Patent: November 18, 1997Assignees: The General Hospital Corporation, Boston University, Dana-Farber Cancer InstituteInventors: E. Antonio Chiocca, David J. Waxman, Ming X. Wei, Xandra O. Breakefield, Ling Chen